Patents Assigned to MONTELINO THERAPEUTICS, LLC
  • Publication number: 20200239430
    Abstract: The present invention relates to bi-functional compounds which function to recruit endogenous proteins to an E3 ubiquitin ligase for degradation, and methods for using same. More specifically, the present disclosure provides specific proteolysis targeting chimera (PROTAC) molecules which find utility as modulators of targeted ubiquitinization of a variety of polypeptides and other proteins, in particular the androgen receptor of a slice variant of AR which lacks the LBD, labelled as AR-V7, which are then degraded and/or otherwise inhibited by the compounds as described herein.
    Type: Application
    Filed: January 30, 2020
    Publication date: July 30, 2020
    Applicant: MONTELINO THERAPEUTICS, LLC
    Inventors: Jenny Desantis, Roy Joseph Vaz, Isaac Kim